Tel Aviv, Israel

Avikam Harel

USPTO Granted Patents = 5 


Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 170(Granted Patents)


Company Filing History:


Years Active: 1996-2017

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Avikam Harel: Innovator in Dermatological Treatments

Introduction

Avikam Harel is a prominent inventor based in Tel Aviv, Israel. He has made significant contributions to the field of dermatology, particularly in the treatment of hyperproliferative epidermal diseases. With a total of 5 patents to his name, Harel's work has the potential to impact many lives suffering from skin disorders.

Latest Patents

Harel's latest patents focus on compositions and methods for treating hyperproliferative epidermal diseases. One of his notable inventions provides pharmaceutical compositions for topical administration that consist essentially of a vitamin D metabolite, calcipotriol, and nicotinamide. These compositions are particularly effective in treating psoriasis and other related dermal disorders. Another patent also emphasizes the use of nicotinamide and calcipotriol for similar therapeutic purposes, showcasing Harel's commitment to advancing dermatological treatments.

Career Highlights

Throughout his career, Avikam Harel has worked with various companies, including Dermipsor Ltd. and Amron Corporation. His experience in these organizations has allowed him to develop innovative solutions for skin-related health issues. Harel's dedication to research and development in dermatology has established him as a key figure in this field.

Collaborations

Harel has collaborated with notable professionals in his field, including Zeev Even-Chen and Olga Bloch. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Avikam Harel's contributions to dermatology through his innovative patents demonstrate his commitment to improving the treatment of skin diseases. His work continues to pave the way for new therapeutic options for patients suffering from hyperproliferative epidermal diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…